Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESK981 in Select Solid Tumors
NCT05988918Phase 2Active, not recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Apr 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CEP-11981 in pancreatic adenocarcinoma (PDAC), adenosquamous carcinoma (ASC), Pancreatic neuroendocrine tumor (PanNET), pancreatic neuroendocrine carcinoma (PNEC), gastrointestinal neuroendocrine tumor, sponsored by University of Michigan Rogel Cancer Center. Started Apr 2024; status: active, not recruiting.
02
Drugs
CEP-11981
03
Conditions
pancreatic adenocarcinoma (PDAC)adenosquamous carcinoma (ASC)Pancreatic neuroendocrine tumor (PanNET)pancreatic neuroendocrine carcinoma (PNEC)gastrointestinal neuroendocrine tumor
Beyond the preview
Go deeper on NCT05988918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05988918.